What are the odds of contracting Japanese encephalitis as a traveler to Asia?
Evidence quality 4.63/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 5/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 4/5
- D4 Uncertainty
- 5/5
- D5 Scope
- 5/5
- D6 Prose
- 4/5
- D7 Perception honesty
- 4/5
- D8 Caveat completeness
- 5/5
Lifetime probability · lifetime, activity-specific
1 in 2,000,000
0.00005% lifetime chance
range 1 in 10,000,000 to 1 in 1,000,000
● your factors — click this risk ▾ to reveal
≈ As likely as
Perceived
Japanese encephalitis is a staple of pre-travel clinic anxiety: a mosquito-borne brain infection, endemic to huge stretches of Asia, with a case fatality rate in the 20–30% range and serious neurological sequelae in a similar share of survivors. The framing is technically accurate and quietly terrifying, and the standard traveler response is to pay several hundred dollars for a two-dose vaccine before a two-week trip to Bangkok. We haven’t found a rigorous recent survey that isolates "fear of Japanese encephalitis" from general travel-disease worry, so the perceived side of this page is marked as editorial intuition rather than polled data. The working prior we observe in travel clinics is "this is a real risk I need to protect against" — which, for the typical short-term urban traveler, is roughly three orders of magnitude too high.
Rough estimate: most travelers leaving a travel clinic treat this as a 1-in-1,000-to-1-in-10,000 trip risk
Source: editorial intuition, not polled
Actual
~1 case per 1,000,000 travelers to endemic Asia
short-term travelers from non-endemic countries to JE-endemic Asia
Show derivation
The CDC Yellow Book and ACIP MMWR both put overall JE incidence among travelers from non-endemic countries at <1 case per million travelers to JE-endemic Asia. Hills, Griggs & Fischer (2010), reviewing every published traveler case 1973–2008, arrived at the same estimate from a completely separate case pool. The point estimate here (5 × 10⁻⁷) represents a short-term (<1 month) traveler whose visit is restricted to major urban areas — the group the CDC describes as at "minimal risk" — which sits a factor of roughly 2 below the headline <1-in-1,000,000 for "any traveler." The scope is activity_specific_lifetime: per traveler-trip, not per adult lifetime. A reader taking multiple short Asia trips across a lifetime still sits well below 1 in 100,000. The upper edge of the uncertainty band uses the headline 1 × 10⁻⁶ figure; the lower edge reflects vaccinated or very-short urban-only itineraries where multiple published reviews find essentially zero cases.
Caveats: The <1-per-million headline figure is an average across all travelers to JE-e…
The <1-per-million headline figure is an average across all travelers to JE-endemic Asia, and the average hides a very wide spread. A two-week business trip to Tokyo or a weekend in Seoul is effectively zero-risk; a six-month rural posting in Bihar or the Mekong Delta during the wet season can approach the local susceptible-resident rate of 6–11 per 100,000 per year. This entry is a per-trip figure for the typical short-term urban traveler, not a per-adult-lifetime figure, and not a substitute for itinerary-specific advice from a qualified travel-medicine clinician. Note also that this entry measures the risk of contracting JE, not of dying from it: the case fatality rate among symptomatic cases is in the 20–30% range (WHO), so the per-trip death risk is roughly another factor of 4–5 lower than the incidence figure shown here.
Regional breakdown
The headline figure averages across very different populations. Here’s how the probability varies by geography or context:
| Region / context | Lifetime probability | Notes |
|---|---|---|
| Short-term urban traveler (<1 month, major cities) | 1 in 2,000,000 |
CDC Yellow Book describes this group as 'minimal risk'; on the order of ~1 per 2 million trips. |
| Any traveler to JE-endemic Asia (all durations, unstratified) | 1 in 1,000,000 |
CDC / ACIP headline figure: <1 case per million travelers. |
| Long-term rural traveler (1+ month, wet season, rural endemic area) | 1 in 10,000 |
Hills et al. highest-risk subgroup: ~65% of documented traveler cases had stayed >=1 month. CDC says this group approaches the pediatric resident rate of 6-11/100,000/year. |
| Endemic rural resident (susceptible child, for reference — not a traveler risk) | 1 in 100 |
Native exposure risk anchor, not a traveler figure. Routine JE vaccination is now standard in endemic-country childhood schedules. |
| Vaccinated traveler (full 2-dose schedule, any itinerary) | 1 in 10,000,000 |
Post-licensure effectiveness is very high; no JE cases have been reported in travelers who completed a full vaccine course per published reviews. |
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
Hepatitis A (travel)
What are the odds of contracting hepatitis A as an unvaccinated traveler to an endemic region?
Traveler's diarrhea (water)
What are the odds of getting seriously ill from drinking water while traveling to a developing country?
Travelers' diarrhea
What are the odds of getting travelers' diarrhea on an international trip to a high-risk destination?
Cosmetic surgery abroad risk
What are the odds of a serious complication from cosmetic surgery abroad?
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
Japanese encephalitis is one of the rarest things that can happen to a traveler to Asia. Both the CDC Yellow Book and the ACIP’s own vaccine recommendations put the overall incidence among travelers from non-endemic countries at less than one case per million travelers, and a peer-reviewed 36-year review by Hills, Griggs, and Fischer (2010) arrived at the same figure from a completely separate pipeline: 55 published traveler cases across 17 countries between 1973 and 2008. Apply the WHO’s case fatality rate of up to 30% and the resulting per-trip mortality sits on the order of 1 in 5 million — roughly an order of magnitude rarer than being killed in a single commercial airline flight. For short-term travelers staying in major cities, the CDC explicitly describes the risk as “minimal,” which is about as close to zero as a public health agency ever commits to in writing.
What makes this fear interesting is that the official framing is accurate and still generates the wrong behavior. Japanese encephalitis really is a severe disease: in the 20–30% of symptomatic cases that are fatal, and the additional 20–30% of survivors left with permanent neurological sequelae, the individual tragedy is real. But the stratification that matters — rural plus wet season plus long duration — routinely gets lost between the travel clinic and the patient. The modal outcome is a backpacker with a one-week Bangkok layover paying several hundred dollars for a two-dose vaccine that the ACIP itself says is not recommended for their itinerary. Hills et al. found that roughly two-thirds of the traveler cases with detailed exposure data had stayed a month or more in endemic areas; the one-week urban tourist is essentially absent from the case series.
The number does not travel across subgroups. For a resident child in a rural endemic area without vaccination coverage, the incidence is on the order of 6–11 per 100,000 per year — four orders of magnitude above the short-term-traveler figure on this page, and the reason JE is a public health priority across the WHO South-East Asia and Western Pacific regions despite being a footnote on the traveler risk ledger. For an expatriate posted to a rural endemic area for a year, Hills et al. suggest the risk approaches that resident figure, and the math then genuinely favors vaccination. For a two-week urban tourist in Tokyo, Seoul, or Bangkok, the probability this page is describing is indistinguishable from zero, and the cost-benefit case for the vaccine collapses accordingly. The disease is serious. The typical traveler’s exposure to it is not.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] US Centers for Disease Control and Prevention — Japanese Encephalitis — CDC Yellow Book
Japanese Encephalitis — CDC Yellow BookSee all 2 Likelier entries citing this source →
- Statistic
Overall incidence of JE among travelers from non-endemic countries is estimated at <1 case per 1 million travelers; short-term (<1 month) travelers restricted to major urban areas are at minimal risk; long-term rural travelers may approach the susceptible pediatric resident rate of 6-11 cases per 100,000 children per year.- Excerpt
“"The overall incidence of JE among people from non-endemic countries traveling to Asia is estimated to be <1 case per 1 million travelers. … Shorter-term (e.g., <1 month) travelers whose visits are restricted to major urban areas are at minimal risk for JE. … Expatriates and travelers staying prolonged periods in rural areas with active JE virus transmission might be at similar risk as the susceptible pediatric resident population, which is 6–11 cases per 100,000 children per year." ”
- Source data from
- 2024-05-01
- Accessed
- 2026-04-11 · archived copy
- Calculation
- CDC Yellow Book gives the headline traveler figure (<1 per million) used as the upper edge of the uncertainty band, and the long-term rural figure (6–11 per 100,000 per year) used as the anchor for the "long-term rural traveler, 1+ month wet season" row of regional_breakdown. The short-term urban point estimate of 5 × 10⁻⁷ is the CDC’s <1 per million divided by a factor of 2 to reflect the "minimal risk" subgroup language.
- Independence
- CDC Yellow Book is the primary US traveler-facing clinical guidance, synthesised from CDC programmatic estimates and the peer-reviewed travel-medicine literature. Shares CDC publisher and authorship overlap with the ACIP MMWR recommendations (Hills et al. co-authored both); Hills et al. 2010 and WHO are the meaningfully independent cross-checks.
-
[2] American Journal of Tropical Medicine and Hygiene (Hills, Griggs, Fischer) — Japanese encephalitis in travelers from non-endemic countries, 1973–2008
Japanese encephalitis in travelers from non-endemic countries, 1973–2008- Statistic
55 published JE cases in travelers from 17 non-endemic countries over 1973-2008; 10 deaths (18%); 24 (44%) with sequelae; 65% of detailed-assessment cases had spent >=1 month in endemic areas; overall estimate <1 case per million travelers.- Excerpt
“"We identified 55 JE cases in travelers or expatriates from 17 non-endemic countries. … Ten (18%) patients died and 24 (44%) had sequelae. … Among 37 case-patients with detailed risk assessment, 24 (65%) had spent ≥ 1 month in JE-endemic areas. … The overall risk of JE for travelers to JE-endemic countries is estimated to be less than 1 case/1 million travelers." ”
- Source data from
- 2010-05-01
- Accessed
- 2026-04-11 · archived copy
- Calculation
- Hills et al. is the peer-reviewed anchor for the <1 per million figure and for the long-duration-rural skew: roughly two-thirds of traveler cases with detailed data occurred in people who had spent a month or more in endemic areas. This is the empirical basis for the ~200× personal_factor_multiplier on "long-term rural stay." Drawn from a case pool (published traveler case reports 1973–2008) that is methodologically independent of the CDC programmatic estimate, so it counts as genuine corroboration rather than restatement.
- Independence
- Hills et al. is a published case-series review; the CDC Yellow Book figure derives from CDC’s programmatic estimates and case reporting. The two overlap (Hills is a CDC author) but use different pipelines, so treat as partially dependent.
-
[3] US CDC / MMWR Recommendations and Reports (Hills et al.) — Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices
Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices- Statistic
Overall JE incidence among US travelers 1993-2017 estimated at <1 case per million trips to Asia; vaccine not recommended for short-term urban-only itineraries or travel outside the transmission season.- Excerpt
“"The overall incidence of JE among persons from nonendemic countries who travel to Asia is estimated to be less than one case per 1 million travelers. … JE vaccine is not recommended for travelers with very low-risk itineraries, such as shorter-term travel limited to urban areas or travel that occurs outside of a well-defined JE virus transmission season." ”
- Source data from
- 2019-07-19
- Accessed
- 2026-04-11 · archived copy
- Calculation
- ACIP’s own recommendation text explicitly does NOT recommend the vaccine for short-term urban-only itineraries. This is the primary citation for the "debunked" myth_framing: the official body tasked with vaccine policy agrees that the risk for the modal Asia tourist is too low to warrant the vaccine.
- Independence
- Shares CDC upstream with the Yellow Book entry; used here for the explicit vaccine-policy framing rather than a second independent estimate of incidence.
-
[4] World Health Organization — Japanese encephalitis — Fact sheet
Japanese encephalitis — Fact sheet- Statistic
~100,000 clinical JE cases per year globally (95% CI: 61,720-157,522); case fatality rate up to 30%; 20-30% of survivors suffer permanent cognitive, behavioural or neurological sequelae; 24 countries in SE Asia and Western Pacific have transmission risk covering >3 billion people.- Excerpt
“"There are an estimated about 100 000 clinical cases (95% CI: 61 720– 157 522) of JE globally each year. … The case fatality rate can be as high as 30% among those with disease symptoms. … Of those who survive, 20–30% suffer permanent cognitive, behavioural or neurological sequelae such as seizures. … Twenty-four countries in the WHO South-East Asia and Western Pacific Regions have JEV transmission risk, which includes more than 3 billion people." ”
- Source data from
- 2024-05-09
- Accessed
- 2026-04-11 · archived copy
- Calculation
- WHO provides the severity anchor: ~30% case fatality and ~20-30% sequelae among survivors. Applied to the short-term traveler point estimate of 5 × 10⁻⁷, the per-trip death risk is on the order of 1 in 6-7 million and the per-trip severe-sequelae risk is of similar magnitude — an order of magnitude rarer than being killed in a commercial plane crash per flight.
- Independence
- WHO figure is based on the Campbell et al. (2011) Bulletin of the WHO global burden estimate, independent of the CDC traveler-specific numbers.